Lior Shaltiel
Chief Executive Officer at NUREXONE BIOLOGIC INC.
Net worth: 198 475 $ as of 29/04/2024
Profile
Dr. Lior Shaltiel is a Chief Executive Officer & Director at NurExone Biologic Ltd.
and a Chief Executive Officer & Director at NurExone Biologic, Inc. He is on the Board of Directors at NurExone Biologic Ltd.
and NurExone Biologic, Inc.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
NUREXONE BIOLOGIC INC
0.77% | 15/05/2024 | 425,000 ( 0.77% ) | 198 475 $ | 29/04/2024 |
Lior Shaltiel active positions
| Companies | Position | Start |
|---|---|---|
| NUREXONE BIOLOGIC INC. | Chief Executive Officer | 31/03/2021 |
NurExone Biologic Ltd.
 NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Chief Executive Officer | 31/03/2021 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| NUREXONE BIOLOGIC INC. | Health Technology |
| Private companies | 1 |
|---|---|
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Health Technology |
- Stock Market
- Insiders
- Lior Shaltiel